| Document |
Document Title |
|
WO/2023/056714A1 |
The present application relates to an aromatization method for a nitrogen-containing heterocyclic compound. The aromatization method for a nitrogen-containing heterocyclic compound comprises: in a solvent, using a nitrogen-containing het...
|
|
WO/2023/056033A1 |
Disclosed herein are novel lipids that can be used in combination with other lipid components, such as helper lipids, structural lipids, and cholesterols, to form lipid nanoparticles for delivery of therapeutic agents, such as nucleic ac...
|
|
WO/2023/049438A1 |
Provided herein are compounds (e.g., compounds of Formula (I)), and pharmaceutically acceptable salts, stereoisomers, tautomers, isotopically labeled derivatives, solvates, hydrates, polymorphs, co-crystals, and prodrugs thereof, pharmac...
|
|
WO/2023/045910A1 |
The present application discloses a small-molecule compound having a naphthol ether structure, and a use thereof. Disclosed in the present application are a compound having a structure represented by general formula (I), a pharmaceutical...
|
|
WO/2023/031375A1 |
Disclosed herein are compounds of formula (I). In particular, the compounds are metallodrug therapeutic compounds or prodrugs of metallodrug therapeutic compounds. The metallodrug therapeutic compounds and prodrugs of metallodrug therape...
|
|
WO/2023/031319A1 |
The present invention relates to novel 2,4-dihydro-3H-1,2,4-triazol-3-one compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for prepar...
|
|
WO/2023/033180A1 |
The present invention provides a plant disease control agent that has low toxicity to human and animals and excellent handling safety, and that exhibits an excellent controlling effect on a wide range of plant diseases and exhibits a hig...
|
|
WO/2023/028597A1 |
The disclosure describes compounds of Formula la, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-piAR binding moiety. Compounds of Formula la are useful in preventing, treating, an...
|
|
WO/2023/024425A1 |
A triazolone compound represented by formula (I), a medicinal use thereof and a pharmaceutical composition comprising the compound. The compound has a potent agonistic effect on PPARα and PPARδ, may be applied in the preparation of a P...
|
|
WO/2023/007147A1 |
This invention relates to therapeutic 6-substituted naphthalene-1,3- disulfonic acid derivatives of formula (I) (Formula (I)). More specifically, the invention relates to compounds of formula (I) useful as modulators of extracellular nic...
|
|
WO/2023/285883A1 |
Disclosed herein are embodiments of a bi-functionalized dicyclopentadiene monomer and polymer embodiments formed therefrom. The monomer embodiments exhibit tunability and can be used to form thermally stable homopolymers, copolymers, and...
|
|
WO/2023/285175A1 |
The invention relates to compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for protecting ...
|
|
WO/2023/282110A1 |
A nematocidal composition is provided that exhibits excellent nematocidal properties. This invention relates to a nematocidal composition that contains, as an effective component, a compound represented in formula (I) or a salt thereof...
|
|
WO/2023/280237A1 |
A synthesis and an application of a phosphatase degrader, belonging to the field of chemical medicine. The phosphatase degrader is a compound represented by formula I, or a salt thereof, or a deuterated compound thereof, or a stereoisome...
|
|
WO/2023/279205A1 |
The present technology relates to UV radiation-absorbing and/or visible radiation-absorbing compounds, and use of same in the preparation of compositions for protecting biological and nonbiological material against UV and/or visible radi...
|
|
WO/2023/281505A1 |
The invention provides compounds and uses thereof in the treatment and prevention of diseases and conditions associate with or aggravated by impaired mitophagy or oxidative stress, and methods of their preparation.
|
|
WO/2023/272793A1 |
A fluorine-containing graft copolymer, a preparation method therefor and the use thereof. The preparation method of the fluorine-containing graft copolymer comprises the following steps: reacting a compound as shown in formula (I) and a ...
|
|
WO/2023/277517A1 |
The present invention relates to a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof, which, by inhibiting the replication of an RNA virus by being integrated as a nucleotide derivative into a polym...
|
|
WO/2022/269113A1 |
The present invention relates to new compounds of formula (I) that act as CXCR4 receptor ligands. The invention also relates to the use thereof to treat and/or prevent diseases mediated by said receptor, such as cancer, HIV infection or ...
|
|
WO/2022/271840A1 |
Indazole compounds are provided that are selective inhibitors of human LRRK2.
|
|
WO/2022/266753A1 |
There are provided conjugates of Formula (V) wherein R1 is a triantennary targeting moiety comprising N-acetyl galactosamine and R2 is a bioactive agent which is preferably an oligonucleotide, as well as pharmaceutical compositions and m...
|
|
WO/2022/263829A1 |
The invention relates to compounds or salts of Formula (I-a), Formula (I-b), Formula (I-c), Formula (I-d), Formula (II) and pharmaceutical compositions containing these compounds. The compounds may be inducers of α1-antitrypsin (A1AT), ...
|
|
WO/2022/262814A1 |
A triazole sulfonamide derivative containing oxime ether fragments, a preparation method therefor and an application thereof, and a bactericide and an application thereof. The derivative has a structure represented by formula (I). The co...
|
|
WO/2022/262657A1 |
The present invention relates to an N-substituted phenylsulfonamide compound and a use thereof. Specifically, the present invention provides a compound represented by formula I, or an optical isomer thereof, or a racemate thereof, or a p...
|
|
WO/2022/258792A1 |
The present invention relates to new cinnamic add amides which may be used for treatment of fibrosis and neoplasia and to cinnamic acid amides for use in the treatment of fibrosis, neoplasia, arthrolithiasis, familiar mediterranean fever...
|
|
WO/2022/253645A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2022/256419A1 |
Compounds and compositions are provided as inhibitors of the Wnt/beta-catenin pathway and/or activators of the adenosine monophosphate-activated kinase (AMPK) pathway for the treatment of diseases that implicate the same. Such diseases i...
|
|
WO/2022/243097A1 |
A process to produce N-vinyl compounds by homogeneous catalysis, wherein acetylene is re-acted with a compound having at least one nitrogen bearing a substitutable hydrogen residue in a liquid phase in the presence of at least one phosph...
|
|
WO/2022/235220A1 |
Disclosed herein are two compounds that are used together to form a PROTAC molecule in situ. Thus, there is a compound of formula Ia and a compound of formula Ib: where R1, R2, L1, L2, X and Y are described herein.
|
|
WO/2022/228286A1 |
The present invention relates to the field of medicinal chemistry, and disclosed are a class of biphenyl derivatives having PD-1/PD-L1 inhibitory activity, a preparation method therefor and a use thereof. Further disclosed are a composit...
|
|
WO/2022/228402A1 |
A triazole sulfonamide derivative containing alkenyl fragments represented by formula (I), a preparation method therefor and an application thereof, and a bactericide comprising the derivative and an application thereof. The derivatives ...
|
|
WO/2022/221451A2 |
Sulfonyl-triazole compounds and related sulfonyl-heterocycle compounds are described. Exemplary compounds can form covalent adducts with reactive nucleophilic amino acid residues in proteins, such as reactive tyrosines, to form modified ...
|
|
WO/2022/221181A1 |
The present invention relates to compounds represented by Formulae (I) to (V), or a racemate, enantiomer, diastereomer, pharmaceutically acceptable salt, solvate, hydrate, or derivative thereof, and compositions thereof. In various aspec...
|
|
WO/2022/214995A1 |
The present invention relates to compounds of formula (I), wherein X is –OH, -N(CH3)2, (II) or (III) or (IV); Y is CH or N; and Z is (V), (VI), (VII), (VIII) or (IX) and salts, solvates and solvates of the salts thereof.
|
|
WO/2022/189856A9 |
This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising...
|
|
WO/2022/206862A1 |
A compound represented by formula (I) and a pharmaceutically acceptable salt thereof, as well as an antifungal application of the compound.
|
|
WO/2022/196927A1 |
The present invention relates to a composition for prevention or treatment of neurofibromatosis type 2 syndrome. In contrast to the conventional TβR1 kinase inhibitor TEW7197, the compound represented by chemical formula 1, a pharmaceut...
|
|
WO/2022/188792A1 |
The present invention relates to a compound of formula (I), a pharmaceutical composition comprising same, a preparation method therefor, and a use thereof for preventing or treating tumor-related diseases or conditions.
|
|
WO/2022/192562A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
|
|
WO/2022/190648A1 |
The present invention provides a non-aqueous electrolyte which includes a metal-organic framework having a sufficiently high adsorption amount of carbon dioxide. The present invention relates to a non-aqueous electrolyte including a meta...
|
|
WO/2022/190129A1 |
The present invention provides a synergistic herbicidal composition comprising Glufosinate-ammonium and at least two compounds selected from the group comprising Mesotrione, Oxyfluorfen, Atrazine, 2,4-D and uses thereof.
|
|
WO/2022/187206A1 |
Disclosed herein are novel dual-target compounds that bind at both the mu-opioid receptor (MOR) and dopamine D3 receptors (D3R) to provide MOR-mediated analgesia, while minimizing addictive liability through D3R antagonism/partial agonis...
|
|
WO/2022/187041A1 |
Provided herein are various metallopolymers and methods of making the same.
|
|
WO/2022/182057A1 |
The present invention relates to a novel triazolyl combretastatin derivative and a composition containing same as an active ingredient for prevention or treatment of corona virus infection disease. The novel triazolyl combretastatin deri...
|
|
WO/2022/180647A1 |
The present provides a synergistic herbicidal composition comprising Pinoxaden, Carfentrazone-ethyl and at least one herbicidal compound selected from Fenoxaprop-p-ethyl or Isoproturon, and uses thereof.
|
|
WO/2022/177016A1 |
Provided is a method for manufacturing an azole derivative with little by-product. The present invention provides a method for manufacturing an azole derivative represented by general formula (I), said method comprising: a step for react...
|
|
WO/2022/174882A1 |
The present invention relates to a compounds of general formula (I) inhibiting both lysophosphatidic acid receptor 1 (LPA1) and receptor 2 (LPA2), particularly the invention relates to compounds that are 5-membered heterocyclyl carbamate...
|
|
WO/2022/178228A1 |
The invention provides arylthioether acetamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxA activity.
|
|
WO/2022/172994A1 |
The present invention provides a method for producing an oligonucleotide having a phosphate ester bond by oxidizing an oligonucleotide precursor having a phosphite ester bond or a phosphonic acid ester bond via an oxidizing agent, wherei...
|
|
WO/2022/166990A1 |
Provided in the present invention are a 2-(substituted phenoxy)aromatic formic acid FTO inhibitor, a preparation method therefor and the use thereof, and specifically disclosed are a compound represented by formula (I), and the use of a ...
|
